Medicare Part B Inflation Rebate List Doubles For Third Quarter, Adds Several Amgen Drugs
Amgen's Prolia appears to be the biggest drug on the list of products incurring price inflation penalties in Part B; many of the others have relatively low sales to Medicare.
You may also be interested in...
CMS’ latest update to the list of products subject to inflation rebates in the Part B brings the total number of different products that will owe rebates in the first year of the new penalty to 64. The headlines about big savings do not match the reality of very modest liabilities for the affected manufacturers.
The Centers for Medicare and Medicaid Services has a lot on its plate and is under intense stakeholder scrutiny as it implements the price control provisions of the Inflation Reduction Act.
Biden Administration releases first list of Part B drugs subject to inflation rebates; others to follow on quarterly basis. Medicare won’t invoice sponsors until 2025, but patients could see coinsurance reductions next month.